Information de reference pour ce titreAccession Number: | 00005064-200919040-00002.
|
Author: | Gloeckner, Christian Johannes *; Schumacher, Annette *; Boldt, Karsten *,+; Ueffing, Marius *,+
|
Institution: | (*)Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Department of Protein Science, Neuherberg, Germany (+)Institute of Human Genetics, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany
|
Title: | |
Source: | Journal of Neurochemistry. 109(4):959-968, May 2009.
|
Abstract: | : Autosomal dominant mutations in the human Leucine-Rich Repeat Kinase 2 (LRRK2) gene represent the most common monogenetic cause of Parkinson disease (PD) and increased kinase activity observed in pathogenic mutants of LRRK2 is most likely causative for PD-associated neurotoxicity. The sequence of the LRRK2 kinase domain shows similarity to MAP kinase kinase kinases. Furthermore, LRRK2 shares highest sequence homology with mixed linage kinases which act upstream of canonical MAPKK and are involved in cellular stress responses. Therefore, we addressed the question if LRRK2 exhibits MAPKKK activity by systematically testing MAPKKs as candidate substrates, in vitro. We demonstrate that LRRK2 variants phosphorylate mitogen-activated protein kinase kinases (MAPKK), including MKK3 -4, -6 and -7. MKKs act upstream of the MAPK p38 and JNK mediating oxidative cell stress, neurotoxicity and apoptosis. The disease-associated LRRK2 G2019S and I2020T mutations show an increased phosphotransferase activity towards MKKs correlating with the activity shown for its autophosphorylation. Our findings present evidence of a new class of molecular targets for mutant LRRK2 that link to neurotoxicity, cellular stress, cytoskeletal dynamics and vesicular transport.
(C) 2009 International Society for Neurochemistry
|
Author Keywords: | LRRK2; MKK3; MKK4; MKK6; MKK7; Parkinson disease.
|
References: | Biskup S. and West A. B. (2008) Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim. Biophys. Acta [Epub ahead of print] doi: 10.1016/j.bbadis.2008.09.015.
Biskup S., Moore D. J., Rea A., Lorenz-Deperieux B., Coombes C. E., Dawson V. L., Dawson T. M. and West A. B. (2007) Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci. 8, 102.
Borsello T. and Forloni G. (2007) JNK signalling: a possible target to prevent neurodegeneration. Curr. Pharm. Des. 13, 1875-1886.
Bosgraaf L. and Van Haastert P. J. (2003) Roc, a Ras/GTPase domain in complex proteins. Biochim. Biophys. Acta 1643, 5-10.
Brice A. (2005) Genetics of Parkinson's disease: LRRK2 on the rise. Brain 128, 2760-2762.
Brown K., Vial S. C., Dedi N., Long J. M., Dunster N. J. and Cheetham G. M. (2005) Structural basis for the interaction of TAK1 kinase with its activating protein TAB1. J. Mol. Biol. 354, 1013-1020.
Burke R. E. (2007) Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacol. Ther. 114, 261-277.
Cookson M. R., Dauer W., Dawson T., Fon E. A., Guo M. and Shen J. (2007) The roles of kinases in familial Parkinson's disease. J. Neurosci. 27, 11865-11868.
Deng J., Lewis P. A., Greggio E., Sluch E., Beilina A. and Cookson M. R. (2008) Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc. Natl Acad. Sci. USA 105, 1499-1504.
Derijard B., Raingeaud J., Barrett T., Wu I. H., Han J., Ulevitch R. J. and Davis R. J. (1995) Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267, 682-685.
Farrer M., Stone J., Mata I. F., Lincoln S., Kachergus J., Hulihan M., Strain K. J. and Maraganore D. M. (2005) LRRK2 mutations in Parkinson disease. Neurology 65, 738-740.
Gallo K. A. and Johnson G. L. (2002) Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol. 3, 663-672.
Gloeckner C. J., Kinkl N., Schumacher A., Braun R. J., O'Neill E., Meitinger T., Kolch W., Prokisch H. and Ueffing M. (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15, 223-232.
Gloeckner C. J., Boldt K., Schumacher A., Roepman R. and Ueffing M. (2007) A novel tandem affinity purification strategy for the efficient isolation and characterization of native protein complexes. Proteomics 7, 4228-4234.
Horiuchi D., Collins C. A., Bhat P., Barkus R. V., Diantonio A. and Saxton W. M. (2007) Control of a kinesin-cargo linkage mechanism by JNK pathway kinases. Curr. Biol. 17, 1313-1317.
Iaccarino C., Crosio C., Vitale C., Sanna G., Carri M. T. and Barone P. (2007) Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum. Mol. Genet. 16, 1319-1326.
Ito G., Okai T., Fujino G., Takeda K., Ichijo H., Katada T. and Iwatsubo T. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46, 1380-1388.
Jaleel M., Nichols R. J., Deak M., Campbell D. G., Gillardon F., Knebel A. and Alessi D. R. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 405, 307-317.
Lesage S., Durr A., Tazir M., Lohmann E., Leutenegger A. L., Janin S., Pollak P. and Brice A. (2006) LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 354, 422-423.
Lewis P. A., Greggio E., Beilina A., Jain S., Baker A. and Cookson M. R. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun. 357, 668-671.
Li X., Tan Y. C., Poulose S., Olanow C. W., Huang X. Y. and Yue Z. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem. 103, 238-247.
Liou A. K., Leak R. K., Li L. and Zigmond M. J. (2008) Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway. Neurobiol. Dis. 32, 116-124.
Luzon-Toro B., de la Torre E. R., Delgado A., Perez-Tur J. and Hilfiker S. (2007) Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum. Mol. Genet. 16, 2031-2039.
MacLeod D., Dowman J., Hammond R., Leete T., Inoue K. and Abeliovich A. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587-593.
Manning G., Whyte D. B., Martinez R., Hunter T. and Sudarsanam S. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934.
Marin I. (2006) The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol. Biol. Evol. 23, 2423-2433.
Mata I. F., Kachergus J. M., Taylor J. P. et al. (2005) Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6, 171-177.
Mata I. F., Wedemeyer W. J., Farrer M. J., Taylor J. P. and Gallo K. A. (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 29, 286-293.
Nolen B., Taylor S. and Ghosh G. (2004) Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell 15, 661-675.
Ozelius L. J., Senthil G., Saunders-Pullman R. et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354, 424-425.
Paisan-Ruiz C., Jain S., Evans E. W. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600.
Raingeaud J., Whitmarsh A. J., Barrett T., Derijard B. and Davis R. J. (1996) MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol. Cell. Biol. 16, 1247-1255.
Rodriguez-Viciana P., Tetsu O., Tidyman W. E., Estep A. L., Conger B. A., Cruz M. S., McCormick F. and Rauen K. A. (2006) Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311, 1287-1290.
Schwede T., Kopp J., Guex N. and Peitsch M. C. (2003) SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res. 31, 3381-3385.
Smith W. W., Pei Z., Jiang H., Moore D. J., Liang Y., West A. B., Dawson V. L., Dawson T. M. and Ross C. A. (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl Acad. Sci. USA 102, 18676-18681.
Smith W. W., Pei Z., Jiang H., Dawson V. L., Dawson T. M. and Ross C. A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9, 1231-1233.
Takekawa M., Tatebayashi K. and Saito H. (2005) Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. Mol. Cell 18, 295-306.
Tournier C., Whitmarsh A. J., Cavanagh J., Barrett T. and Davis R. J. (1999) The MKK7 gene encodes a group of c-Jun NH2-terminal kinase kinases. Mol. Cell. Biol. 19, 1569-1581.
West A. B., Moore D. J., Biskup S., Bugayenko A., Smith W. W., Ross C. A., Dawson V. L. and Dawson T. M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA 102, 16842-16847.
West A. B., Moore D. J., Choi C. et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16, 223-232.
White L. R., Toft M., Kvam S. N., Farrer M. J. and Aasly J. O. (2007) MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. J. Neurosci. Res. 85, 1288-1294.
Zimprich A., Biskup S., Leitner P. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607.
|
Language: | English.
|
Document Type: | ORIGINAL ARTICLES.
|
Journal Subset: | Clinical Medicine. Behavioral & Social Sciences.
|
ISSN: | 0022-3042
|
NLM Journal Code: | jav, 2985190r
|
DOI Number: | https://dx.doi.org/10.1111/j.147...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|